Sesame, a leading cash-pay healthcare platform, has announced a new collaboration with Novo Nordisk as a NovoCare Recognized Care Provider to support the nationwide rollout of the Wegovy pill. Through this partnership, patients across the United States can use the Sesame website or mobile app to book appointments with licensed providers and gain access to the first FDA-approved oral GLP-1 medication for weight loss.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
The Wegovy pill introduces a new oral option for people seeking obesity treatment, offering an alternative to injectable therapies. Dave Moore, Executive Vice President of US Operations at Novo Nordisk, shared that the oral formulation expands choice for patients while making care easier to access. He explained that working with Sesame allows Novo Nordisk to reach people directly through a care model designed around simplicity and individual needs, helping patients move forward with treatment more confidently.
Health Technology Insights: CareTrust Acquires $142 Million Mid-Atlantic Nursing Portfolio
Sesame operates on an affordability-focused approach that removes insurance intermediaries and provides clear, upfront pricing. Patients can select their own provider from Sesame’s nationwide network and often schedule same-day video visits in all fifty states. Having already served more than one million patients and earned a satisfaction rate of ninety-five percent, Sesame has built a strong reputation for accessible and transparent healthcare services.
According to David Goldhill, Co-Founder and Chief Executive Officer of Sesame, the collaboration is intended to make the Wegovy pill more attainable for people who might otherwise face cost or access barriers. He noted that Sesame’s direct-to-patient model gives individuals a clear understanding of pricing before booking care, helping them avoid unexpected expenses. By simplifying the process, Sesame aims to ensure that more people can benefit from innovative weight loss treatments without navigating complex insurance rules.
Through its platform, Sesame connects patients with licensed healthcare professionals who can evaluate whether the Wegovy pill is appropriate and prescribe it when clinically indicated. The provider network includes primary care physicians, specialists, and nurse practitioners who offer both virtual and in-person care options. Patients can review provider profiles, choose who they want to see, and view exact visit costs in advance, including pricing for video consultations and ongoing messaging support.
Sesame’s structured weight management program begins at ninety-nine dollars per month and includes continuous virtual care, messaging with a dedicated provider, laboratory testing to track progress, and guidance on lifestyle factors such as nutrition, physical activity, and sleep. The program also supports the use of insurance for GLP-1 medications and other weight loss treatments, while maintaining self-pay options for those without coverage. Patients can access a range of FDA-approved therapies, including the Wegovy pill and pen, with medication pricing starting at twenty-five dollars per month for commercially insured individuals or one hundred forty-nine dollars per month for self-pay patients.
Health Technology Insights: Natera Launches 21-Gene Fetal Focus Single-Gene NIPT
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
